Atai Life Sciences and Introspect Digital Therapeutics will be testing a novel, digital therapeutic approach for patients using ketamine for treatment resistant depression.
The clinical-stage biopharmaceutical company, atai Life Sciences, which aims to transform the treatment of mental health disorders, along with its digital therapeutic platform – Introspect Digital Therapeutics, Inc. – will be carrying out a usability study of Introspect’s digital therapeutic (DTx) app technology in supporting standard of care ketamine therapy for patients with treatment resistant depression.
The study will be carried out in collaboration with Kadima Neuropsychiatry.
Digital therapeutics
Introspect’s DTx app approach to supported treatment in mental health will be integrated across three cohorts.
Cohort 1 will be focusing on user acceptability, Cohort 2 will be examining the introduction of therapeutic content via the app, and Cohort 3 will be assessing set and setting of the treatment.
The company says it believes that high-quality digital combination therapies have the potential to improve the safety and effectiveness of many mental health treatments, and that it considers DTx to be vital to the mission of providing personalised and scalable treatment to those who might not otherwise be able to access high-quality psychological care.
CEO of Introspect, David Keene, commented: “We’re thrilled to be working with Kadima to test our digital therapeutic approach in a clinical setting with patients receiving with standard of care ketamine therapy.
“Our goal is to show that our novel DTx app can be used alongside a drug; that it is useful, usable and intuitive to patients and providers.”
“The integration of Introspect’s digital therapeutic in a clinical environment is a pivotal step towards developing potentially scalable care,” added Florian Brand, co-founder and CEO of atai.
“In our mission to improve the lives of millions living with mental health disorders, technology will be instrumental, ensuring that our pipeline of novel compounds can benefit patients everywhere.”
